Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975085 · ClinicalTrials.gov registry record · Phase 2
Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 781
- Enrollment target
NCT06975085 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 781 participants.
The verdict
NCT06975085, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 781 participants
- Enrollment target
Study Summary
The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.
Interventions
- BEHAVIORAL Presentation of a personal breast cancer risk estimate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 781 participants |
| Start Date | 2025-04-16 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06975085
The ClinicalTrials.gov registry entry for NCT06975085 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 781 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Presentation of a personal breast cancer risk estimate is the first listed.
NCT06975085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06975085 about?
NCT06975085 is a clinical study titled "Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study". The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.
What is the current status of trial NCT06975085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 781 participants. The study started on 2025-04-16. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT06975085?
The interventions under investigation include: Presentation of a personal breast cancer risk estimate (BEHAVIORAL).
Who is sponsoring clinical trial NCT06975085?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.